RFX 1 regulates CD 70 and CD 11 a expression in lupus T cells by recruiting the histone methyltransferase SUV 39 H 1
Ming Zhao,Xiaoyan Wu,Qing Zhang,Shuangyan Luo,Gongping Liang,Yuwen Su,Yixin Tan,Qianjin Lu
2011-01-01
Abstract:Introduction: Regulatory factor X-box 1 (RFX1) can interact with DNA methyltransferase 1 (DNMT1) and histone deacetylase 1 (HDAC1), and RFX1 down-regulation contributes to DNA hypomethylation and histone H3 hyperacetylation at the cluster of differentiation (CD) 11a and CD70 promoters in CD4 T cells of patients with systemic lupus erythematosus (SLE). This leads to CD11a and CD70 overexpression, thereby triggering autoimmune responses. In order to provide more insight into the epigenetic mechanisms leading to the deregulation of autoimmune-related genes in SLE, we asked whether RFX1 is involved in regulating histone 3 lysine 9 (H3K9) trimethylation at the CD11a and CD70 promoters in SLE CD4 T cells. Methods: CD4 T cell samples were isolated from 15 SLE patients and 15 healthy controls. H3K9 tri-methylation levels were measured by chromatin immunoprecipitation (ChIP) and real-time quantitative PCR. CD4 T cells were transfected with plasmids using the Human T cell Nucleofector Kit. RFX1 and histone methyltransferase suppressor of variegation 3-9 (Drosophila) homolog 1 (SUV39H1) interaction was determined by co-immunoprecipation (co-IP) and Western blot and immunofluorescence staining. CD11a and CD70 mRNA levels were measured by real-time RT-PCR. Results: H3K9 tri-methylation levels were significantly reduced within the CD11a and CD70 promoter regions in SLE CD4 T cells. RFX1 co-immunoprecipitated with SUV39H1 at the CD11a and CD70 promoters in healthy control CD4 T cells. Overexpressing or knocking-down RFX1 revealed that RFX1 expression correlated with H3K9 trimethylation levels, as well as CD11a and CD70 expression levels in CD4 T cells. Conclusions: RFX1 recruits SUV39H1 to the promoter regions of the CD11a and CD70 genes in CD4 T cells, thereby regulating local H3K9 tri-methylation levels. These findings shed further light on the central role of RFX1 down-regulation in the epigenetic de-repression of auto-immune genes in SLE. Introduction Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by excess production of autoantibodies. Multiple studies have demonstrated the important role of epigenetic alterations in triggering the hyper-activation of T lymphocytes that leads to lupus and lupus-like diseases [1-3]. T-cell autoreactivity in lupus is thought to be due in part to the overexpression of adhesion molecule lymphocyte function-associated antigen 1 (LFA-1, composed of cluster of differentiation (CD) 11a and CD18 subunits) [4,5], and of CD70 (TNFSF7), which induces B cells to over-produce autoantibodies [6,7]. Our previous studies have confirmed that DNA hypomethylation and histone hyperacetylation of CD11a and CD70 promoter regions contribute to their overexpression in SLE CD4 T cells [8-10]. However, the mechanisms leading to deregulated epigenetic modifications at the CD11a and CD70 gene loci are not completely understood. The transcription factor regulatory factor X-box 1 (RFX1), the first cloned member of the RFX family, is down-regulated in CD4 T cells of SLE patients [11]. RFX1 contains a C-terminal repressive region, an overlapping dimerization domain, and an N-terminal * Correspondence: dermatology20091@yahoo.cn Department of Dermatology, Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenomics, No. 139 Renmin Middle Rd, Changsha, Hunan 410011, PR China Zhao et al. Arthritis Research & Therapy 2010, 12:R227 http://arthritis-research.com/content/12/6/R227 © 2010 Zhao et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. activation domain, and is capable of both activating and repressing target gene transcription [0] depending on the cellular context [12]. Although the mechanisms by which RFX1 exerts its activation or repression activity have only been partially elucidated, it is known that RFX1 behaves as a potent transcriptional repressor in CD4 T cells [10]. In these cells, RFX1 binds to target genes, including CD11a and CD70, and recruits the transcriptional co-repressors histone deacetylase 1 (HDAC1) and DNA methyltransferase1 (DNMT1). This leads to local histone hypoacetylation and DNA hypermethylation and consequently to the suppression of target gene expression [10]. In a previous study, we found that RFX1 is significantly down-regulated in SLE CD4 T cells. We also demonstrated that RFX1 forms a stable complex with HDAC1 and DNMT1 in the nucleus of CD4 T cells, and that down-regulating RFX1 in these cells increases histone acetylation and decreases DNA methylation at the CD11a and CD70 promoter regions, epigenetic changes that lead to the de-repression of CD11a and CD70 [10]. Another epigenetic mechanism for repressing gene transcription is the methylation of specific lysine residues in histones, a modification that is critical to shaping repressive chromatin structures [13,14]. Among the histone methyltransferases involved in this process, the best characterized is the suppressor of variegation 3-9 (Drosophila) homolog 1 (SUV39H1). By tri-methylating lysine 9 in histone H3 (H3K9) SUV39H1 is able to generate a binding site for the transcriptional repressor heterochromatin-associated protein 1 (HP1) [15,16]. Therefore, H3K9 tri-methylation is involved in gene repression and serves as a marker for the establishment of a stable heterochromatin configuration [17]. In the present study, we show that RFX1 binds to CD11a and CD70 promoter DNA in CD4 T cells where it recruits SUV39H1 and regulates H3K9 tri-methylation levels. We further reveal that the down-regulation of RFX1 in SLE CD4 T cells reduces local H3K9 tri-methylation levels around the promoters of CD11a and CD70, thus further contributing to the de-repression of these critical auto-immune factors. Materials and methods Patients and controls Patient demographics and treatment regimens are shown in Table 1. SLE patients (mean age 27 ± 6 yrs) were recruited from outpatient clinics of the Second Xiangya Hospital Central South University. All patients fulfilled at least four of the SLE classification criteria of the American College of Rheumatology [18]. Lupus disease activity was assessed using the SLE Disease Activity Index (SLEDAI) [19]. Healthy controls (mean age 25 ± 3 yrs) were recruited from medical staff at the Second Xiangya Hospital. This study was approved by the human ethics committee of the Central South University Xiangya Medical School, and written informed consent was obtained from all subjects. Patients and controls were ageand sex-matched in all experiments. Isolation, culturing and transfection of T cells A total of 60 ml of venous peripheral blood was withdrawn from each patient and control subject and preserved with heparin. CD4 T cells were isolated by positive selection using CD4 beads, according to protocols provided by the manufacturer (Miltenyi, Bergisch Gladbach, Germany; purity was generally higher than 95%), and cultured in human T cell culture medium (Lonza, Walkersville, MD, USA). CD4 T cells were transfected with plasmids using the Human T cell Nucleofector Kit and Amaxa nucleofector (Lonza). In brief, CD4 T cells were harvested and resuspended in 100 μl human T cell nucleofector solution. The cell suspension was then mixed with 10 μg empty plasmids (pSUPER or pSG5) or plasmid vectors encoding an RFX1-targeting siRNA (pSuper.RFX1) or full-length RFX1 cDNA (pSG5-RFX1, both provided by Dr. Yosef Shaul, Weizmann Institute of Science, Rehovot, Israel). The mix was electrotransfected using the nucleofector program V-024 in the Amaxa nucleofector. Transfected cells were cultured in human T cell culture medium and harvested 48 hours later. Chromatin immunoprecipitation (ChIP) ChIP analysis was performed according to the instructions provided with the ChIP assay kit (Millipore, Billerica, MA, USA). In brief, CD4 T cells were fixed for eight minutes at RT with 1% formaldehyde. Glycine was then Table 1 Patient demographics and medications Patient SLEDAI score Medications